Anti Cd 20 Ocrevus denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Ocrevus as Experimental — and Why This Denial Is Contestable

Ocrelizumab (Ocrevus) received FDA approval for both relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. A denial categorizing it as "experimental" or "investigational" is therefore factually incorrect when the drug is prescribed for an FDA-approved indication. This type of denial most often occurs because UHC's coverage policy has a narrow definition of what qualifies as established therapy for a particular MS subtype — most frequently primary progressive MS, for which earlier-generation DMTs were not approved — or because the claim was submitted with an off-label diagnosis code.

Because FDA approval is a matter of public record and because major neurology professional societies (including the American Academy of Neurology) have incorporated ocrelizumab into their MS treatment guidance, this denial has strong grounds for reversal.

## Your Federal Appeal Rights

• Internal appeal: You are entitled to a full-and-fair internal review under ERISA §503 (employer plans) or applicable state law. File within the deadline on your denial notice — commonly 180 days.
• External review: Under ACA §2719, experimental/investigational denials are explicitly subject to independent external review. An accredited Independent Review Organization applies clinical and scientific evidence standards, not UHC's internal policy definitions. The filing window is approximately four months from final internal denial. Expedited review (72-hour decision) is available for urgent clinical situations.
• External review is particularly powerful here: IROs frequently reverse experimental denials for FDA-approved therapies, particularly when denial criteria conflict with peer-reviewed consensus.

## Concrete Steps and Timeline

1. Request the denial letter in writing. It must cite the specific UHC coverage policy language and the definition of "experimental" being applied. 2. Obtain UHC's published Medical Policy for ocrelizumab. Compare the policy's experimental/investigational criteria against (a) the FDA-approved labeling and (b) applicable professional society guidelines. 3. Verify the diagnosis code submitted. Confirm the ICD-10 code on the claim and prior-authorization request precisely matches the FDA-approved indication for the MS subtype being treated. 4. File the internal appeal with the documentation below. Explicitly state that ocrelizumab is FDA-approved for the submitted indication. 5. If the internal appeal is denied, escalate to external review immediately and frame the appeal around the FDA-approval record and societal guideline support.

## Documentation to Gather

• FDA approval documentation: A copy of or reference to the FDA approval letter for Ocrevus and the approved indication language (publicly available on FDA.gov).
• Diagnosis confirmation matching the approved indication: Neurologist chart notes and MRI reports documenting the MS subtype with precision — particularly important for primary progressive MS.
• Prescriber medical-necessity letter: A detailed letter from your neurologist (a) confirming the FDA-approved indication applies to your diagnosis, (b) referencing applicable AAN or ECTRIMS guideline support, and (c) rebutting the experimental characterization with published clinical evidence.
• Clinical severity documentation: EDSS or equivalent functional assessment, relapse records, MRI lesion progression, and any evidence of disease activity justifying treatment.
• Prior treatment history: Chart notes showing what prior DMTs were used (if any) and why ocrelizumab is the appropriate current choice.

## Criteria-Mapping Structure

Obtain UHC's Medical Policy in full. For each criterion used to classify a therapy as non-experimental, map your evidence:

| Policy Criterion | Your Evidence | |---|---| | FDA approval for submitted indication | FDA label, indication text for [RRMS / PPMS] | | Professional society guideline support | AAN guideline reference; neurologist letter citing same | | Diagnosis code matches approved indication | ICD-10 code on claim; neurologist diagnostic note |

An experimental denial for an FDA-approved agent is one of the most frequently reversed denial types in external review. Act promptly to preserve the four-month window.